Frank Guido K W, Shott Megan E, Hagman Jennifer O, Schiel Marissa A, DeGuzman Marisa C, Rossi Brogan
Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Department of Neuroscience, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.
Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target.
Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program.
The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment.
The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.
寻找支持神经性厌食症治疗的药物一直颇具难度。基于神经科学的方法或许有助于此。近期针对患有神经性厌食症的成人和青少年的脑成像研究表明，与多巴胺相关的奖赏回路高度敏感，可能提供一个治疗靶点。
在此，我们对106名患有神经性厌食症的青少年进行了一项回顾性病历审查，其中部分青少年在一个专门的饮食失调项目治疗期间接受了多巴胺D2受体部分激动剂阿立哌唑的治疗。
结果显示，在治疗期间，阿立哌唑治疗与体重指数（BMI）的更大增幅相关。
多巴胺受体激动剂的使用可能有助于神经性厌食症治疗取得成功，应进一步开展研究。
